Sanofi says in talks with Genzyme over key drug

French drugmaker Sanofi Aventis SA said on Sunday it was in discussions with US bid target Genzyme Corp over ways to value a key Genzyme drug, but there was no guarantee an agreement would be reached.

January 10, 2011 / 09:31 IST

French drugmaker Sanofi Aventis SA said on Sunday it was in discussions with US bid target Genzyme Corp over ways to value a key Genzyme drug, but there was no guarantee an agreement would be reached.

Sanofi has offered to acquire Genzyme, a maker of drugs for rare diseases, for USD 18.5 billion, or USD 69 a share -- a figure Genzyme says is too low.

first published: Jan 10, 2011 09:24 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347